Apicidin confers promising therapeutic effect on acute myeloid leukemia cells via increasing QPCT expression

References

• Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375n2026:n2026. doi:10.1136/bmj.n2026.
   PubMedGoogle Scholar
• Thomas X, Elhamri M, Heiblig M. Emerging pharmacotherapies for elderly acute myeloid leukemia patients. Expert Rev Hematol. 2020;13(6):619–11. doi:10.1080/17474086.2020.1758058.
   PubMed Web of Science ®Google Scholar
• Rowe JM. Changing trends in the therapy of acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(4):101333. doi:10.1016/j.beha.2021.101333.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;127(8):1186–1207. doi:10.1002/cncr.33477.
   PubMed Web of Science ®Google Scholar
• Kishtagari A, Levine RL, Viny AD. Driver mutations in acute myeloid leukemia. Curr Opin Hematol. 2020;27(2):49–57. doi:10.1097/MOH.0000000000000567.
   PubMed Web of Science ®Google Scholar
• Cerrano M, Itzykson R. New treatment options for acute Myeloid Leukemia in 2019. Curr Oncol Rep. 2019;21(2):16. doi:10.1007/s11912-019-0764-8.
   PubMed Web of Science ®Google Scholar
• Ball B, Mei M, Otoukesh S, Stein A. 2021. Current and emerging therapies for acute Myeloid Leukemia. Cancer Treat Res. 181:57–73.
   PubMedGoogle Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD, Longo DL. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra1406184.
   PubMed Web of Science ®Google Scholar
• Goldman SL, Hassan C, Khunte M, Soldatenko A, Jong Y, Afshinnekoo E, Mason CE. Epigenetic modifications in acute Myeloid Leukemia: prognosis, treatment, and heterogeneity. Front Genet. 2019;10:133. doi:10.3389/fgene.2019.00133.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao X, Yu L. Roles of histone deacetylases in acute Myeloid Leukemia with fusion proteins. Front Oncol. 2021;11:741746. doi:10.3389/fonc.2021.741746.
   PubMed Web of Science ®Google Scholar
• Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone Deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes (Basel). 2020;11(5):11. doi:10.3390/genes11050556.
   Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10(1):32–42. doi:10.1038/nrg2485.
   PubMed Web of Science ®Google Scholar
• Li Y, Seto E. Hdacs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6(10):6. doi:10.1101/cshperspect.a026831.
   Web of Science ®Google Scholar
• Mehrpouri M, Pourbagheri-Sigaroodi A, Bashash D. The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. Int Immunopharmacol. 2021;100:108114. doi:10.1016/j.intimp.2021.108114.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang J, Zhang X, Cheng P, Liu L, Huang Q, Liu H, Ren S, Wei P, Wang C, et al. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. J Mol Med (Berl). 2021;99(1):107–118. doi:10.1007/s00109-020-01998-5.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Y, Zhou Y, Li J, Chen K, Zhang L, Deng M, Deng S, Li P, Xu B, et al. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics. 2017;9(1):83. doi:10.1186/s13148-017-0377-8.
   PubMedGoogle Scholar
• Li G, Li D, Yuan F, Cheng C, Chen L, Wei X. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism. Ann Transl Med. 2021;9(20):1575. doi:10.21037/atm-21-5066.
   PubMed Web of Science ®Google Scholar
• Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee Y-W, Lee H-W, Han J-W, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem. 2002;277(3):2073–2080. doi:10.1074/jbc.M106699200.
   PubMed Web of Science ®Google Scholar
• Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009;69(14):1911–1934. doi:10.2165/11315680-000000000-00000.
   PubMed Web of Science ®Google Scholar
• You JS, Kang JK, Seo DW, Park JH, Park JW, Lee JC, Jeon YJ, Cho EJ, Han J-W. Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Research. 2009;69(14):5716–5725. doi:10.1158/0008-5472.CAN-08-4953.
   PubMed Web of Science ®Google Scholar
• Ezura Y, Kajita M, Ishida R, Yoshida S, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Orimo H, et al. Association of multiple nucleotide variations in the pituitary glutaminyl cyclase gene (QPCT) with low radial BMD in adult women. J Bone Miner Res. 2004;19(8):1296–1301. doi:10.1359/JBMR.040324.
   PubMed Web of Science ®Google Scholar
• Cheng H, Cheng T. ‘Waterloo’: when normal blood cells meet leukemia. Curr Opin Hematol. 2016;23(4):304–310. doi:10.1097/MOH.0000000000000253.
   PubMed Web of Science ®Google Scholar
• Chen MT, Dong L, Zhang XH, Yin XL, Ning HM, Shen C, Su R, Li F, Song L, Ma Y-N, et al. ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6. Sci Rep. 2015;5(1):16229. doi:10.1038/srep16229.
   PubMedGoogle Scholar
• Chen MT, Lin HS, Shen C, Ma YN, Wang F, Zhao HL, Yu J, Zhang J-W. PU.1-regulated long noncoding RNA lnc-MC controls human monocyte/macrophage differentiation through interaction with MicroRNA 199a-5p. Molecular And Cellular Biology. 2015;35(18):3212–3224. doi:10.1128/MCB.00429-15.
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer Journal. 2016;6(7):e441. doi:10.1038/bcj.2016.50.
   PubMed Web of Science ®Google Scholar
• Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015;126(22):2491–2501. doi:10.1182/blood-2015-05-646240.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Park TS, Wan TS. 2017. Recurrent cytogenetic abnormalities in acute Myeloid Leukemia. Methods Mol Biol. 1541:223–245.
   PubMedGoogle Scholar
• Foucar K, Anastasi J. Acute Myeloid Leukemia with recurrent cytogenetic abnormalities. Am J Clin Pathol. 2015;144(1):6–18. doi:10.1309/AJCPI9C8UILYQTNS.
   PubMed Web of Science ®Google Scholar
• Huang HT, Figueroa ME. Epigenetic deregulation in myeloid malignancies. Blood. 2021;138(8):613–624. doi:10.1182/blood.2019004262.
   PubMed Web of Science ®Google Scholar
• Liu XL, Liu HQ, Li J, Mao CY, He JT, Zhao X. Role of epigenetic in leukemia: from mechanism to therapy. Chem Biol Interact. 2020;317:108963. doi:10.1016/j.cbi.2020.108963.
   PubMed Web of Science ®Google Scholar
• Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19(1):5. doi:10.1186/s12943-019-1127-7.
   PubMed Web of Science ®Google Scholar
• Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid Leukemia. Hemasphere. 2021;5(6):e572. doi:10.1097/HS9.0000000000000572.
   PubMed Web of Science ®Google Scholar
• Bohl SR, Bullinger L, Rucker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11(5):361–371. doi:10.1080/17474086.2018.1453802.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752.
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute Myeloid Leukemia. Cancers Basel. 2019;11(11):11. doi:10.3390/cancers11111794.
   Web of Science ®Google Scholar
• Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep. 2006;15:489–494. doi:10.3892/or.15.2.489.
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs S, Carey N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581–589. doi:10.1042/BJ20070779.
   PubMed Web of Science ®Google Scholar
• Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu X-P, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–909. doi:10.1007/s00280-011-1766-x.
   PubMed Web of Science ®Google Scholar
• Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. Semin Cancer Biol. 2020;83:452–471. doi:10.1016/j.semcancer.2020.07.015.
   PubMed Web of Science ®Google Scholar
• Spreafico M, Gruszka AM, Valli D, Mazzola M, Deflorian G, Quinte A, Totaro MG, Battaglia C, Alcalay M, Marozzi A, et al. HDAC8: a promising therapeutic target for acute Myeloid Leukemia. Front Cell Dev Biol. 2020;8:844. doi:10.3389/fcell.2020.00844.
   PubMed Web of Science ®Google Scholar